Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBV-specific T-cell lines for EBV infection or lymphoma
NCT02580539Phase 2Completed
- Start
- Nov 2015
- Primary completion
- May 2025
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Native Immune Cells
- Countries
- 1
01
Overview
A Phase 2 trial of baltaleucel-T in Epstein-Barr virus infection, Post-Transplant Lymphoproliferative Disorder (PTLD), lymphoma. Started Nov 2015; status: completed.
02
Drugs
baltaleucel-T
03
Conditions
Epstein-Barr virus infectionPost-Transplant Lymphoproliferative Disorder (PTLD)lymphoma
Beyond the preview
Go deeper on NCT02580539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02580539.